Shandong University is conducting a multicentered clinical trial looking at the safety and efficacy of using a combination of hetrombopag (a thrombopoietin-receptor agonist) plus high-dose dexamethasone (a corticosteroid) for the treatment of adults over 18 years of age with a platelet count less than 30,000 or less than 50,000 with bleeding in newly diagnosed primary immune thrombocytopenia (ITP).
China
Actively Recruiting